ID   LOX5_RAT                Reviewed;         673 AA.
AC   P12527;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   24-JUL-2024, entry version 172.
DE   RecName: Full=Polyunsaturated fatty acid 5-lipoxygenase {ECO:0000305};
DE            EC=1.13.11.- {ECO:0000250|UniProtKB:P09917};
DE   AltName: Full=Arachidonate 5-lipoxygenase;
DE            Short=5-LO {ECO:0000250|UniProtKB:P09917};
DE            Short=5-lipoxygenase {ECO:0000303|PubMed:3417684};
DE            EC=1.13.11.34 {ECO:0000250|UniProtKB:P09917};
GN   Name=Alox5 {ECO:0000312|RGD:2096};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3417684; DOI=10.1016/s0021-9258(18)68334-6;
RA   Balcarek J.M., Theisen T.W., Cook M.N., Varrichio A., Hwang S.-M.,
RA   Strohsacker M.W., Crooke S.T.;
RT   "Isolation and characterization of a cDNA clone encoding rat 5-
RT   lipoxygenase.";
RL   J. Biol. Chem. 263:13937-13941(1988).
RN   [2]
RP   SEQUENCE REVISION TO 667-670.
RX   PubMed=8518276; DOI=10.1021/bi00076a003;
RA   Minor W., Steczko J., Bolin J.T., Otwinowski Z., Axelrod B.;
RT   "Crystallographic determination of the active site iron and its ligands in
RT   soybean lipoxygenase L-1.";
RL   Biochemistry 32:6320-6323(1993).
CC   -!- FUNCTION: Catalyzes the oxygenation of arachidonate to 5-
CC       hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to
CC       5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps
CC       in the biosynthesis of leukotrienes, which are potent mediators of
CC       inflammation. Also catalyzes the oxygenation of arachidonate into 8-
CC       hydroperoxyicosatetraenoate (8-HPETE) and 12-
CC       hydroperoxyicosatetraenoate (12-HPETE). Displays lipoxin synthase
CC       activity being able to convert (15S)-HETE into a conjugate tetraene.
CC       Although arachidonate is the preferred substrate, this enzyme can also
CC       metabolize oxidized fatty acids derived from arachidonate such as
CC       (15S)-HETE, eicosapentaenoate (EPA) such as (18R)- and (18S)-HEPE or
CC       docosahexaenoate (DHA) which lead to the formation of specialized pro-
CC       resolving mediators (SPM) lipoxin and resolvins E and D respectively,
CC       therefore it participates in anti-inflammatory responses (By
CC       similarity). Oxidation of DHA directly inhibits endothelial cell
CC       proliferation and sprouting angiogenesis via peroxisome proliferator-
CC       activated receptor gamma (PPARgamma). It does not catalyze the
CC       oxygenation of linoleic acid and does not convert (5S)-HETE to lipoxin
CC       isomers. In addition to inflammatory processes, it participates in
CC       dendritic cell migration, wound healing through an antioxidant
CC       mechanism based on heme oxygenase-1 (HO-1) regulation expression,
CC       monocyte adhesion to the endothelium via ITGAM expression on monocytes.
CC       Moreover, it helps establish an adaptive humoral immunity by regulating
CC       primary resting B cells and follicular helper T cells and participates
CC       in the CD40-induced production of reactive oxygen species (ROS) after
CC       CD40 ligation in B cells through interaction with PIK3R1 that bridges
CC       ALOX5 with CD40. May also play a role in glucose homeostasis,
CC       regulation of insulin secretion and palmitic acid-induced insulin
CC       resistance via AMPK. Can regulate bone mineralization and fat cell
CC       differentiation increases in induced pluripotent stem cells (By
CC       similarity). {ECO:0000250|UniProtKB:P09917,
CC       ECO:0000250|UniProtKB:P48999}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = H2O + leukotriene A4;
CC         Xref=Rhea:RHEA:32307, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:57463; EC=1.13.11.34;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32308;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=18-HEPE + O2 = (5S)-hydroperoxy-18-hydroxy-
CC         (7E,9E,11Z,14Z,16E)-eicosapentaenoate; Xref=Rhea:RHEA:48860,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:90825, ChEBI:CHEBI:90826;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48861;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(18R)-hydroxy-(5Z,8Z,11Z,14Z,16E)-eicosapentaenoate + O2 =
CC         (5S)-hydroperoxy-(18R)-hydroxy-(6E,8Z,11Z,14Z,16E)-eicosapentaenoate;
CC         Xref=Rhea:RHEA:51968, ChEBI:CHEBI:15379, ChEBI:CHEBI:90818,
CC         ChEBI:CHEBI:132218; Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51969;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(18S)-hydroxy-(5Z,8Z,11Z,14Z,16E)-eicosapentaenoate + O2 =
CC         (5S)-hydroperoxy-(18S)-hydroxy-(6E,8Z,11Z,14Z,16E)-eicosapentaenoate;
CC         Xref=Rhea:RHEA:50204, ChEBI:CHEBI:15379, ChEBI:CHEBI:132083,
CC         ChEBI:CHEBI:132091; Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50205;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroperoxy-(18S)-hydroxy-(6E,8Z,11Z,14Z,16E)-
CC         eicosapentaenoate = (5S,6S)-epoxy-(18S)-hydroxy-(7E,9E,11Z,14Z,16E)-
CC         eicosapentaenoate + H2O; Xref=Rhea:RHEA:39107, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:132091, ChEBI:CHEBI:134661;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39108;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroperoxy-(18R)-hydroxy-(6E,8Z,11Z,14Z,16E)-
CC         eicosapentaenoate = (5S,6S)-epoxy-(18R)-hydroxy-(7E,9E,11Z,14Z,16E)-
CC         eicosapentaenoate + H2O; Xref=Rhea:RHEA:50268, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:132218, ChEBI:CHEBI:132219;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50269;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroperoxy-18-hydroxy-(7E,9E,11Z,14Z,16E)-
CC         eicosapentaenoate = (5S,6S)-epoxy-18-hydroxy-(7E,9E,11Z,14Z,16E)-
CC         eicosapentaenoate + H2O; Xref=Rhea:RHEA:50844, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:90826, ChEBI:CHEBI:133812;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50845;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (5S)-hydroperoxy-
CC         (6E,8Z,11Z,14Z)-eicosatetraenoate; Xref=Rhea:RHEA:17485,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57450;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17486;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + O2 = (5S)-
CC         hydroperoxy-(15S)-hydroxy-(6E,8Z,11Z,13E)-eicosatetraenoate;
CC         Xref=Rhea:RHEA:48624, ChEBI:CHEBI:15379, ChEBI:CHEBI:57409,
CC         ChEBI:CHEBI:131564; Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48625;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroperoxy-(6E,8Z,11Z,14Z)-eicosatetraenoate = H2O +
CC         leukotriene A4; Xref=Rhea:RHEA:17961, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57450, ChEBI:CHEBI:57463;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17962;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (8S)-hydroperoxy-
CC         (5Z,9E,11Z,14Z)-eicosatetraenoate; Xref=Rhea:RHEA:38675,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:75322;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38676;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (12S)-hydroperoxy-
CC         (5Z,8Z,10E,14Z)-eicosatetraenoate; Xref=Rhea:RHEA:10428,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57444;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10429;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z)-eicosadienoate + O2 = (5S)-hydroperoxy-(6E,8Z)-
CC         eicosadienoate; Xref=Rhea:RHEA:62644, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:145835, ChEBI:CHEBI:145836;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(12S)-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + O2 = (5S)-
CC         hydroperoxy-(12S)-hydroxy-(6E,8Z,10E,14Z)-eicosatetraenoate;
CC         Xref=Rhea:RHEA:62648, ChEBI:CHEBI:15379, ChEBI:CHEBI:90680,
CC         ChEBI:CHEBI:145837; Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 = 5-hydroperoxy-
CC         (6E,8Z,11Z,14Z,17Z)-eicosapentaenoate; Xref=Rhea:RHEA:62600,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:58562, ChEBI:CHEBI:145815;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62601;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 = (14S)-
CC         hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate;
CC         Xref=Rhea:RHEA:41332, ChEBI:CHEBI:15379, ChEBI:CHEBI:77016,
CC         ChEBI:CHEBI:78048; Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41333;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 = (7S)-
CC         hydroperoxy-(4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoate;
CC         Xref=Rhea:RHEA:64668, ChEBI:CHEBI:15379, ChEBI:CHEBI:77016,
CC         ChEBI:CHEBI:156049; Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64669;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 = (17S)-
CC         hydroperoxy-(4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoate;
CC         Xref=Rhea:RHEA:50840, ChEBI:CHEBI:15379, ChEBI:CHEBI:77016,
CC         ChEBI:CHEBI:133795; Evidence={ECO:0000250|UniProtKB:P09917};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50841;
CC         Evidence={ECO:0000250|UniProtKB:P09917};
CC   -!- COFACTOR:
CC       Name=Fe cation; Xref=ChEBI:CHEBI:24875;
CC         Evidence={ECO:0000250|UniProtKB:P09917,
CC         ECO:0000255|PROSITE-ProRule:PRU00726};
CC       Note=Binds 1 Fe cation per subunit. {ECO:0000250|UniProtKB:P09917,
CC       ECO:0000255|PROSITE-ProRule:PRU00726};
CC   -!- PATHWAY: Lipid metabolism; leukotriene A4 biosynthesis.
CC       {ECO:0000250|UniProtKB:P09917}.
CC   -!- SUBUNIT: Homodimer. Interacts with ALOX5AP and LTC4S. Interacts with
CC       COTL1, the interaction is required for stability and efficient
CC       catalytic activity. Interacts with PIK3R1; this interaction bridges
CC       ALOX5 with CD40 after CD40 ligation in B cells and leads to the
CC       production of reactive oxygen species (ROS). Interacts (via PLAT
CC       domain) with DICER1 (via Dicer dsRNA-binding fold domain); this
CC       interaction enhances arachidonate 5-lipoxygenase activity and modifies
CC       the miRNA precursor processing activity of DICER1.
CC       {ECO:0000250|UniProtKB:P09917}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P09917,
CC       ECO:0000250|UniProtKB:P48999}. Nucleus matrix
CC       {ECO:0000250|UniProtKB:P09917}. Nucleus membrane
CC       {ECO:0000250|UniProtKB:P09917}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P09917}. Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:P09917}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:P09917}. Nucleus envelope
CC       {ECO:0000250|UniProtKB:P09917}. Nucleus intermembrane space
CC       {ECO:0000250|UniProtKB:P09917}. Note=Shuttles between cytoplasm and
CC       nucleus. Found exclusively in the nucleus, when phosphorylated on Ser-
CC       272. Calcium binding promotes translocation from the cytosol and the
CC       nuclear matrix to the nuclear envelope and membrane association.
CC       {ECO:0000250|UniProtKB:P09917}.
CC   -!- PTM: Serine phosphorylation by MAPKAPK2 is stimulated by arachidonic
CC       acid. Phosphorylation on Ser-523 by PKA has an inhibitory effect.
CC       Phosphorylation on Ser-271 prevents export from the nucleus.
CC       Phosphorylation at Ser-523 is stimulated by 8-bromo-3',5'-cyclic AMP or
CC       prostaglandin E2. {ECO:0000250|UniProtKB:P09917}.
CC   -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA41538.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J03960; AAA41538.1; ALT_FRAME; mRNA.
DR   PIR; A30882; A30882.
DR   RefSeq; NP_036954.1; NM_012822.1.
DR   AlphaFoldDB; P12527; -.
DR   SMR; P12527; -.
DR   DIP; DIP-48659N; -.
DR   IntAct; P12527; 1.
DR   STRING; 10116.ENSRNOP00000017633; -.
DR   BindingDB; P12527; -.
DR   ChEMBL; CHEMBL312; -.
DR   DrugCentral; P12527; -.
DR   GuidetoPHARMACOLOGY; 1385; -.
DR   iPTMnet; P12527; -.
DR   PhosphoSitePlus; P12527; -.
DR   PaxDb; 10116-ENSRNOP00000017633; -.
DR   GeneID; 25290; -.
DR   KEGG; rno:25290; -.
DR   UCSC; RGD:2096; rat.
DR   AGR; RGD:2096; -.
DR   CTD; 240; -.
DR   RGD; 2096; Alox5.
DR   eggNOG; ENOG502QQSP; Eukaryota.
DR   InParanoid; P12527; -.
DR   OrthoDB; 999249at2759; -.
DR   PhylomeDB; P12527; -.
DR   BRENDA; 1.13.11.34; 5301.
DR   Reactome; R-RNO-2142688; Synthesis of 5-eicosatetraenoic acids.
DR   Reactome; R-RNO-2142691; Synthesis of Leukotrienes (LT) and Eoxins (EX).
DR   Reactome; R-RNO-2142700; Synthesis of Lipoxins (LX).
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-9018676; Biosynthesis of D-series resolvins.
DR   Reactome; R-RNO-9018682; Biosynthesis of maresins.
DR   Reactome; R-RNO-9018896; Biosynthesis of E-series 18(S)-resolvins.
DR   Reactome; R-RNO-9020265; Biosynthesis of aspirin-triggered D-series resolvins.
DR   Reactome; R-RNO-9023661; Biosynthesis of E-series 18(R)-resolvins.
DR   Reactome; R-RNO-9026286; Biosynthesis of DPAn-3-derived protectins and resolvins.
DR   Reactome; R-RNO-9026290; Biosynthesis of DPAn-3-derived maresins.
DR   Reactome; R-RNO-9026403; Biosynthesis of DPAn-3-derived 13-series resolvins.
DR   Reactome; R-RNO-9027604; Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives.
DR   UniPathway; UPA00877; -.
DR   PRO; PR:P12527; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005635; C:nuclear envelope; IDA:RGD.
DR   GO; GO:0005641; C:nuclear envelope lumen; ISS:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; ISO:RGD.
DR   GO; GO:0031965; C:nuclear membrane; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IDA:RGD.
DR   GO; GO:0004052; F:arachidonate 12(S)-lipoxygenase activity; IEA:RHEA.
DR   GO; GO:0004051; F:arachidonate 5-lipoxygenase activity; ISS:UniProtKB.
DR   GO; GO:0036403; F:arachidonate 8(S)-lipoxygenase activity; IEA:RHEA.
DR   GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0005506; F:iron ion binding; ISS:UniProtKB.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IBA:GO_Central.
DR   GO; GO:0036336; P:dendritic cell migration; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006959; P:humoral immune response; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISO:RGD.
DR   GO; GO:0002232; P:leukocyte chemotaxis involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:1901753; P:leukotriene A4 biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0019370; P:leukotriene biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0006691; P:leukotriene metabolic process; ISO:RGD.
DR   GO; GO:0002540; P:leukotriene production involved in inflammatory response; ISO:RGD.
DR   GO; GO:0034440; P:lipid oxidation; IBA:GO_Central.
DR   GO; GO:2001301; P:lipoxin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0019372; P:lipoxygenase pathway; IBA:GO_Central.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:1903573; P:negative regulation of response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:1903671; P:negative regulation of sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0061044; P:negative regulation of vascular wound healing; ISS:UniProtKB.
DR   GO; GO:0061045; P:negative regulation of wound healing; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:1904999; P:positive regulation of leukocyte adhesion to arterial endothelial cell; ISS:UniProtKB.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:1900407; P:regulation of cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045598; P:regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0106014; P:regulation of inflammatory response to wounding; ISS:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:1903426; P:regulation of reactive oxygen species biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0055093; P:response to hyperoxia; IEP:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   CDD; cd01753; PLAT_LOX; 1.
DR   Gene3D; 3.10.450.60; -; 1.
DR   Gene3D; 2.60.60.20; PLAT/LH2 domain; 1.
DR   InterPro; IPR000907; LipOase.
DR   InterPro; IPR013819; LipOase_C.
DR   InterPro; IPR036226; LipOase_C_sf.
DR   InterPro; IPR020834; LipOase_CS.
DR   InterPro; IPR020833; LipOase_Fe_BS.
DR   InterPro; IPR001885; LipOase_mml.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   InterPro; IPR036392; PLAT/LH2_dom_sf.
DR   InterPro; IPR042062; PLAT_LOX_verte.
DR   PANTHER; PTHR11771; LIPOXYGENASE; 1.
DR   PANTHER; PTHR11771:SF5; POLYUNSATURATED FATTY ACID 5-LIPOXYGENASE; 1.
DR   Pfam; PF00305; Lipoxygenase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PRINTS; PR00087; LIPOXYGENASE.
DR   PRINTS; PR00467; MAMLPOXGNASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF49723; Lipase/lipooxygenase domain (PLAT/LH2 domain); 1.
DR   SUPFAM; SSF48484; Lipoxigenase; 1.
DR   PROSITE; PS00711; LIPOXYGENASE_1; 1.
DR   PROSITE; PS00081; LIPOXYGENASE_2; 1.
DR   PROSITE; PS51393; LIPOXYGENASE_3; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   Calcium; Cytoplasm; Dioxygenase; Direct protein sequencing; Hydrolase;
KW   Iron; Leukotriene biosynthesis; Lipid metabolism; Membrane; Metal-binding;
KW   Nucleus; Oxidoreductase; Phosphoprotein; Reference proteome.
FT   CHAIN           1..673
FT                   /note="Polyunsaturated fatty acid 5-lipoxygenase"
FT                   /id="PRO_0000220696"
FT   DOMAIN          2..117
FT                   /note="PLAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   DOMAIN          118..673
FT                   /note="Lipoxygenase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00726"
FT   BINDING         17
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         18
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         19
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         44
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         45
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         47
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         79
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         80
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /ligand_note="structural"
FT                   /evidence="ECO:0000250"
FT   BINDING         367
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P09917"
FT   BINDING         372
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P09917,
FT                   ECO:0000255|PROSITE-ProRule:PRU00726"
FT   BINDING         550
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P09917,
FT                   ECO:0000255|PROSITE-ProRule:PRU00726"
FT   BINDING         554
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P09917,
FT                   ECO:0000255|PROSITE-ProRule:PRU00726"
FT   BINDING         673
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00726"
FT   SITE            103
FT                   /note="Essential for stabilizing binding to COTL1"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         271
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09917"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09917"
SQ   SEQUENCE   673 AA;  78087 MW;  536B0BC27CB0A608 CRC64;
     MPSYTVTVAT GSQWFAGTDD YIYLSLIGSA GCSEKHLLDK AFYNDFERGG RDSYDVTVDE
     ELGEIYLVKI EKRKYRLHDD WYLKYITLKT PHDYIEFPCY RWITGEGEIV LRDGCAKLAR
     DDQIHILKQH RRKELETRQK QYRWMEWNPG FPLSIDAKCH KDLPRDIQFD SEKGVDFVLN
     YSKAMENLFI NRFMHMFQSS WHDFADFEKI FVKISNTISE RVKNHWQEDL MFGYQFLNGC
     NPVLIKRCTE LPKKLPVTTE MVECSLERQL SLEQEVQEGN IFIVDYELLD GIDANKTDPC
     THQFLAAPIC LLYKNLANKI VPIAIQLNQT PGEKNPIFLP TDSKYDWLLA KIWVRSSDFH
     IHQTITHLLR THLVSEVFGI AMYRQLPAVH PLFKLLVAHV RFTIAINTKA REQLNCEYGL
     FDKANATGGG GHVQMVQRAV QDLTYSSLCF PEAIKARGMD NTEDIPYYFY RDDGLLVWEA
     IQSFTTEVVS IYYEDDQVVE EDQELQDFVK DVYVYGMRGR KASGFPKSIK SREKLSEYLT
     VVIFTASAQH AAVNFGQYDW CSWIPNAPPT MRAPPPTAKG VVTIEQIVDT LPDRGRSCWH
     LGAVWALSQF QENELFLGMY PEEHFIEKPV KEAMIRFRKN LEAIVSVIAE RNKNKKLPYY
     YLSPDRIPNS VAI
//
